Quick Links

Accreditation/Credit Designation

Physicians' Education Resource®, LLC (PER®)is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 1.5 Contact Hours.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?

Release Date: May 31, 2018
Expiration Date: May 31, 2019
Media: Internet - based


Activity Overview

Information pertaining to the applications of poly(ADP-ribose) polymerase (PARP) inhibitor therapy in the treatment of patients with breast cancer continues to emerge at a rapid pace, with multiple phase III studies yielding important safety and efficacy data. As clinicians who treat patients with breast cancer, it is imperative for you to have a solid understanding of the mechanistic rationale for the use of these medications. It is also important for you to be aware of methods that are being studied to help you optimize patient selection for PARP inhibitor therapy, personalize breast cancer treatment approaches for your patients, and mitigate potential treatment-related adverse events.

To help you meet these goals, we have developed an educational activity that features video commentary from leading experts in the management of patients with breast cancer, who will address multiple topics pertaining to the potential use of PARP inhibitors in the treatment of patients with breast cancer.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This activity is directed toward medical oncologists who treat patients with breast cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of breast cancer are invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  1. Explain the mechanistic rationale for the use of PARP inhibition in the treatment of cancer and strategies to optimize patient selection for this therapy
  2. Analyze historical evidence pertaining to the use of PARP inhibition in ovarian and breast cancers
  3. Examine evolving efficacy and safety data concerning the application of PARP inhibitors in the treatment of ovarian and breast cancers, including how this information may inform personalized treatment and mitigation of treatment-related toxicities
  4. Summarize key ongoing studies that address expansion of PARP inhibitor use in different settings for patients with breast cancer

Faculty, Staff, and Planners' Disclosures


Kimberly L. Blackwell, MD
Professor of Medicine
Assistant Professor of Radiation Oncology
Duke University Medical Center
Durham, NC

Disclosure: Grant Research Support: Celgene, Genentech, Pfizer, Novartis; Consultant: Astra Zeneca, Celgene, Celltrion Healthcare, Celldex Therapeutics, Eisai, Eli Lilly, Genentech, Mylan GmbH, Novartis, Pfizer, Pierian Biosciences, Puma, Roche, Syndax, Visante, Seattle Genetics

Susan Domchek, MD
Director, MacDonald Women’s Cancer Risk Evaluation Center
Executive Director, Basser Center for BRCA
Basser Professor in Oncology
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

Disclosure: Honoraria: AstraZeneca, Clovis, BMS.

Sara A. Hurvitz, MD
Associate Professor of Medicine, Division of Hematology/Oncology
Director, Breast Cancer Clinical Research Program
Co-Director, Santa Monica–UCLA Outpatient Hematology/Oncology Practice
David Geffen School of Medicine at UCLA
Santa Monica, CA

Disclosure: Grant Research Support: Amgen, Bayer, BI Pharma, Genentech, GSK, Lilly, Novartis, Pfizer, Roche, Puma, Merrimack, Medivation, Dignitana, OBI Pharma, Biomarin, Cascadian; Travel Support: Lilly, Novartis, OBI Pharma, Bayer.

Jennifer K. Litton, MD
Associate Professor
Department of Breast Medical Oncology and Clinical Cancer Genetics
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosure: Grant Research Support: Pfizer, AstraZeneca, Genentech, GSK, EMD Serono; Consultant: Advisory Boards: Pfizer; AstraZeneca – uncompensated.

Mark E. Robson, MD
Chief, Breast Medicine Service
Attending Physician, Breast Medicine and Clinical Genetics Services
Professor of Medicine, Weill Cornell Medical College
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosure: Grant Research Support: AstraZeneca, AbbVie, Myriad, Medivation, Invitae; Consultant: AstraZeneca, McKesson.

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any of the companies that provided commercial support for this activity.

Become a Member

Forgot Password?
Calendar of Events
Filter By